欧洲制药公司警告欧盟，关税迫在眉睫，它们将迁往美国

Core Viewpoint - Pharmaceutical companies are warning the European Union about the imminent threat of tariffs, which may lead them to relocate to the United States [1] Group 1: Industry Concerns - The European Federation of Pharmaceutical Industries and Associations (EFPIA) stated that the U.S. currently outperforms Europe in all investor metrics, including capital availability, intellectual property, approval speed, and innovation rewards [1] - The increasing tariffs have significantly reduced the incentive for investment in the EU, while the motivation to move to the U.S. has grown substantially [1] Group 2: Financial Implications - A survey conducted by the trade organization revealed that up to 85% of capital expenditure investments and up to 50% of research and development expenditures are at risk, translating to €103.2 billion (approximately $112.9 billion) [1] Group 3: Policy Recommendations - Pharmaceutical companies are urging the EU to fundamentally change its policies, including stronger intellectual property protections and coherent policies regarding environmental and chemical legislation [1] - EFPIA represents around 40 pharmaceutical companies operating in Europe, including Bayer, AstraZeneca, and Novartis [1]